Monthly Op-Ed - Central bankers never get to rest
- Challenges around the virus and vaccine path continue to argue for supportive central banks.
- Proposed US fiscal stimulus is less supportive than headlines would consider.
- Though Fed tapering is someway off, in the interim the Fed might have to consider adjusting the maturity of its purchases.
- Rising earnings per share forecasts and continued low real yields support risk
- Medium-term investment performance at risk from re-pricing of reference rates
- Post-COVID-19 recovery should support markets for now.
New answers got old quickly
By the second half of 2020, central banks could arguably consider their job done in terms of adapting their actual and expected stance to the pandemic emergency. The Federal Reserve (Fed) had set up a steady path of massive purchases of securities and opted for an ultra-dovish forward guidance thanks to their conversion to Average Inflation Targeting, in clear announcing they would tolerate inflation overshooting in the future. The European Central Bank (ECB) announced in December the flexible Pandemic Emergency Purchase Programme (PEPP) would last until March 2022 “at least” with a top up of “at least” EUR500bn, while explicitly acknowledging that their strategy would consist of making the necessary fiscal push possible by keeping governments’ funding costs low.
Since the end of last year, the cyclical outlook has on balance deteriorated. Vaccination programmes – with some exceptions – have been disappointingly slow, and news of production bottlenecks have accumulated. Progress towards collective immunity is frustrating, relative to expectations, strengthening our call that full normalisation would have to wait until the summer, since the emerging variants are fuelling an already stubborn “winter wave”. True, our economies have learned to live with the virus and GDP probably held up better than expected in most developed economies, but the first half of 2021 looks very challenging, with the horizon of lockdown relaxation being pushed further out.
In such an environment, in principle the market would normally demand even more stimulus from central banks. But paradoxically, investors have chosen to question the capacity of the Fed to merely maintain the current quantum of support, worrying earlier than expected about a possible “tapering”, albeit at soonest towards the end of this year. This is of course is in part the result of the massive fiscal stimulus proposed by new President Joe Biden after securing a slim majority in the Senate. The “reflation risk” should be taken with a pinch of salt though. Biden’s USD1.9tn package tops up the USD0.9tn agreed in December, but the combined USD2.8tn is not much bigger than the USD2.5tn of 2020 which has expired for the most part. Considering that Biden’s proposal is an opening gambit and will very likely shrink as the congressional process forces some compromise, it is possible that the fiscal stance will actually tighten in 2021: what matters for GDP growth is the change in the stimulus, not its absolute level. In all likelihood, the pandemic shock in 2021 will be less pronounced than last year, allowing the US economy to perform much better despite a smaller fiscal push, but that the new US administration is erring on the side of caution in providing significant support this year makes sense. Yes, headline inflation will be higher this year than last, with the disappearance of some base effects on oil for instance, but capacity underutilisation should remain significant enough to prevent a “proper”, endogenous acceleration in core inflation.
Even without a strong rebound in inflation, the market should take notice of the higher than expected issuance of US public debt securities brought about by Biden’s plan. This is where the Fed’s stance is challenged. The Fed is very unlikely to taper in the near term, but there is no discussion at all within the central bank on the possibility of scaling up quantitative easing to mop up some of the additional supply of US government paper. This change alone in demand and supply conditions on the bond market could justify the recent rise in long term interest rates. However, the Fed maintains flexibility over the duration of its asset purchases and could raise this later in the year if Janet Yellen’s Treasury increases the duration of its issuance.
The ECB should be in a much better position than the Fed, precisely because it has made plain that they would modulate the quantum and allocation of its emergency quantitative easing to nip in the bud any market-led tightening in market conditions. It may have unfortunately squandered this advantage with a communication issue on 21 January. The ECB pledges to stabilise “financing conditions” but at the latest press conference Christine Lagarde was – understandably – elusive on how it would be measured. It makes sense. The power of the central bank lies partly in the uncertainty it creates for investors who would wish to test its resolve. Mario Draghi would probably have dismissed the question with something like “you will know what the right level is when we act, and you can be sure it will be enough”. This time, it seems the ECB is going to work on a set of criteria at a special seminar in March. The ECB’s strategy, which seemed so clear in December, is being fine-tuned again.
These developments in the US and Europe come at the wrong time: the market needs clarity and anchoring from the central banks at a time of heightened uncertainty on the pandemic front.
Yields and earnings drive markets
Lower real interest rates have been, along with rising earnings forecasts, a key driver of global equity market performance. The current situation remains supportive even if there are concerns about further increases in yields. Real yields have rarely been lower than the current -1% on the 10-year US Treasury inflation linked bond. Compared to the last twenty years the consensus 12-month forecast for the growth in S&P500 currently stands at its 97th percentile ranking. Since global markets bottomed last March, real yields have fallen by 75 basis points (bps) and the consensus 12-month earnings growth forecast has risen from 0% to over 20%. Optimism on earnings is grounded in the view that the global economy will experience a boom once social mobility restrictions are gradually lifted. Optimism on rates is grounded in the view that central banks do have the tools, should they choose, to continue to repress long-term nominal bond yields.
The obvious risk is that things can’t get much better and influence of these drivers on market performance will diminish or even reverse if there are material shifts in the macro environment. Markets could be more vulnerable to a shock – economic or political – and risk a correction from what many argue are rich valuations if earnings growth starts to fade or real yields move a lot higher. Investors in fixed income and equities alike need to pay close attention to the dynamics of the Treasury market, how increased supply impacts on bond prices and whether the Fed will lean against rising yields. Having said that, conditions can remain supportive for risky assets for some time. The fourth quarter (Q4) earnings reporting season in the US has delivered strong upside surprises on both sales and earnings. This bodes well for meeting earnings forecasts for 2021 and beyond Moreover, the level of real rates remains extremely low. Ahead of the two major equity bear markets of the 21st century so far, real yields were 300-500bps higher than today’s levels.
The combination of liquidity and optimism on recovery from the pandemic in a regime of low real returns from risk-free assets should support capital being allocated to higher beta assets. There has been a persistence in the risk-adjusted performance of assets like high yield, leveraged loans, convertible bonds, small-cap equities and emerging markets. These are asset classes associated with generally higher volatility but also with the ability to generate strong returns in those parts of the economic cycle characterised by expansion and easy monetary conditions. Performance deteriorated during the last Fed tightening cycle in 2017-2018 and was hit by the COVID shock last year. However, since then returns have been strong and the search for yield and more diversified returns should be a support going forward.
We would note, however, that valuations are rich. If Treasury yields adjust to a world of stronger growth, higher inflation and a less supportive Fed, then all asset prices are likely to adjust. Ironically, stronger growth could undercut investment returns as the gap between bond and equity yields could converge. However, such a scenario is not for now as investors look towards some genuinely better news as the countries aim for herd immunity from COVID-19.
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.
It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date. All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document. Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.
This document has been edited by AXA INVESTMENT MANAGERS SA, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6 place de la Pyramide, 92800 Puteaux, registered with the Nanterre Trade and Companies Register under number 393 051 826. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.
In the UK, this document is intended exclusively for professional investors, as defined in Annex II to the Markets in Financial Instruments Directive 2014/65/EU (“MiFID”). Circulation must be restricted accordingly.
© AXA Investment Managers 2021. All rights reserved